Core Viewpoint - The company Shih Sih Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Vitamin B6 injection (1ml:0.1g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Vitamin B6 injection is primarily used for the prevention and treatment of Vitamin B6 deficiency [1] - It can also be utilized in cases of pregnancy, radiation sickness, and vomiting caused by anticancer drugs, seborrheic dermatitis, and hereditary Vitamin B6 dependency syndrome in newborns [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, has received approval from the National Medical Products Administration of China for its Vitamin B6 injection (1ml:0.1g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Vitamin B6 injection is primarily used for the prevention and treatment of Vitamin B6 deficiency [1] - It can also be utilized in cases of pregnancy, radiation sickness, and vomiting caused by anticancer drugs, as well as seborrheic dermatitis and hereditary Vitamin B6 dependency syndrome in newborns [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年十一月三日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的維生素 B6 注射液（1ml:0.1g）已取得中國國家藥品監督管理局批准通過仿製藥質量 和療效一致性評價。 維生素 B6 注射液（1ml:0.1g）主要用於維生素 B6 缺乏的預防和治療，也可用於妊娠、放射病 及抗癌藥所致的嘔吐、脂溢性皮炎、新生兒遺傳性維生素 B6 依賴綜合症等。 ...

Summary of Key Points Core Viewpoint - On October 30, 32 Hong Kong-listed companies conducted share buybacks, totaling 34.66 million shares and an aggregate amount of HKD 155 million [1][2]. Group 1: Buyback Details - China Feihe repurchased 12 million shares for HKD 50.23 million, with a highest price of HKD 4.200 and a lowest price of HKD 4.170, bringing its total buyback amount for the year to HKD 129 million [1][2]. - China Petroleum & Chemical Corporation repurchased 4.78 million shares for HKD 19.72 million, with a highest price of HKD 4.220 and a lowest price of HKD 4.100, accumulating a total buyback amount of HKD 794 million for the year [1][2]. - Stone Four Pharmaceutical Group repurchased 5 million shares for HKD 15.41 million, with a highest price of HKD 3.130 and a lowest price of HKD 3.030, totaling HKD 14.81 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on October 30 was from China Feihe at HKD 50.23 million, followed by China Petroleum & Chemical Corporation at HKD 19.72 million [1][2]. - In terms of share quantity, China Feihe led with 12 million shares repurchased, followed by Stone Four Pharmaceutical Group with 5 million shares and China Petroleum & Chemical Corporation with 4.78 million shares [1][2]. Group 3: Additional Buyback Information - Other notable companies involved in buybacks include Lianlian Digital and Guosheng Tang, with varying amounts and share quantities [1][2]. - The data also includes a detailed table of buybacks from various companies, highlighting their respective share counts, amounts, and price ranges [2][3].

Core Insights - A total of 30 companies conducted share buybacks on October 30, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent [1][2] - The total buyback amount for China Feihe was 50.23 million yuan, with 12 million shares repurchased, representing a significant investment in its own stock [1][2] Summary by Company - **China Feihe (06186)**: Repurchased 12 million shares for 50.23 million yuan; cumulative buybacks for the year reached 30.95 million shares, accounting for 0.341% of total share capital [2] - **China Petroleum & Chemical Corporation (00386)**: Repurchased 4.78 million shares for 19.72 million yuan; cumulative buybacks for the year reached 102 million shares, accounting for 0.080% of total share capital [2] - **Stone Four Pharmaceutical Group (02005)**: Repurchased 5 million shares for 15.41 million yuan; cumulative buybacks for the year reached 44.20 million shares, accounting for 1.498% of total share capital [2] - **Lianlian Digital (02598)**: Repurchased 1.38 million shares for 11.31 million yuan; cumulative buybacks for the year reached 4.45 million shares, accounting for 1.065% of total share capital [2] - **Gushengtang (02273)**: Repurchased 290,100 shares for 8.33 million yuan; cumulative buybacks for the year reached 5.88 million shares, accounting for 2.482% of total share capital [2] - **Lianyi Technology-W (09959)**: Repurchased 2.3 million shares for 7.42 million yuan; cumulative buybacks for the year reached 80.04 million shares, accounting for 3.746% of total share capital [2] - **Mongolian Dairy (02319)**: Repurchased 400,000 shares for 5.70 million yuan; cumulative buybacks for the year reached 22.42 million shares, accounting for 0.573% of total share capital [2] - **Kangchen Pharmaceutical (01681)**: Repurchased 280,000 shares for 4.21 million yuan; cumulative buybacks for the year reached 7.84 million shares, accounting for 9.216% of total share capital [2] - **Other Companies**: Various other companies also participated in buybacks, with amounts ranging from 4.51 million yuan to 6 million yuan, and share counts varying significantly [2]

备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 石四药集团 | 曲继广 | 好仓 | 12.17 亿股 | 12.22 亿股 | 41.39%(最新) | | (02005) | | | | | 41.22%(前次) | 智通财经APP获悉，石四药集团(02005)于2025年10月31日进行了最新股东权益披露。 ...

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, has conducted a share buyback on October 30, purchasing 5 million shares at a price range of HKD 3.030 to HKD 3.130, totaling HKD 15.4146 million [2] Summary by Category Share Buyback Activity - The company has executed a total of 17 share buybacks this year, acquiring a cumulative total of 50.1 million shares for a total expenditure of HKD 148 million [2] - On October 30, the closing price of the stock was HKD 3.080, reflecting a decrease of 0.96% for the day, with a total trading volume of HKD 56.6981 million [2] Detailed Buyback Information - The buyback details for October 30 include: - Shares repurchased: 500,000 - Highest buyback price: HKD 3.130 - Lowest buyback price: HKD 3.030 - Total buyback amount: HKD 15.4146 million [2] - A summary of previous buybacks shows varying amounts and prices, with the highest recorded buyback price this year being HKD 3.450 on January 2 [2]

格隆汇10月30日丨石四药集团(02005.HK)发布公告，2025年10月30日耗资1541.5万港元回购500万股， 回购价格每股3.03-3.13港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 石四藥集團有限公司 呈交日期： 2025年10月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Core Viewpoint - The company reported a significant decline in revenue and profit for the nine months ending September 30, 2025, primarily due to decreased sales in intravenous infusion and ampoule injection products, alongside intensified price pressures from expanded procurement initiatives and increased competition in the industry [1] Financial Performance - The company's unaudited revenue for the nine months ending September 30, 2025, was approximately HKD 3.102 billion, representing a year-on-year decrease of 31.6% [1] - The unaudited gross profit for the same period was approximately HKD 1.294 billion, down 46.1% year-on-year, with a gross profit margin of 41.7%, a decline of 11.3 percentage points compared to the previous year [1] - The unaudited profit attributable to shareholders for the nine months was approximately HKD 399 million, reflecting a year-on-year decrease of 56.6% [1]